In a study involving adults with metabolic-associated steatotic liver disease (MASLD), tirzepatide demonstrated a significant 70% reduction in major adverse cardiovascular events (MACE) compared to semaglutide, along with lower hospitalization rates and greater weight loss over three years. The research, presented by Himsikhar Khataniar at the AASLD meeting, indicates that GLP-1/GIP co-agonism may offer enhanced cardiometabolic benefits, including a decreased incidence of myocardial infarction and overall hospitalization. The authors advocate for further clinical trials to confirm the findings.

Source: AASLD